Story perspectives

Neko Health Raises $700 M, Valued at $7 B, Plans US Clinics

7/16/2026

Summary

Neko Health Raises

Neko Health secured $700 million in a Series C round, raising its valuation to almost $7 billion, up from $1.7 billion after a $260 million raise in January 2025.
OG Venture Partners and Lightspeed led the round with Atomico, Mark Zuckerberg, Priscilla Chan and Claudia Schiffer.
It will open U.S. clinics, a New York site in 2026, offering scans for £299.
350,000 have registered; users can take results to the NHS though no data-sharing agreement exists.

Summary

Neko Health Clears

Neko Health secured FDA clearance for core scanning products ahead of its U.S. launch.
Seventy-five percent of members prepay for a follow-up scan after the first visit.
Three-quarters of returning members with flagged serious conditions are now stable or controlled, per company data.
Critics warn that frequent asymptomatic full-body scans may produce false-positives and strain healthcare resources.

History

Historical Context

In 2013-14 Theranos, founded by Elizabeth Holmes, attracted over $700 million and a $9 billion valuation, becoming Silicon Valley’s flagship health-tech darling. Investigative reporting and FDA/SEC actions in 2015 exposed false claims, prompting tighter device oversight and investor skepticism toward diagnostic startups. Neko Health’s $700 million round from investors such as Lightspeed and Mark Zuckerberg now faces similar regulatory scrutiny.

1 of 3

Neko Health Raises

Neko Health secured $700 million in a Series C round, raising its valuation to almost $7 billion, up from $1.7 billion after a $260 million raise in January 2025.
OG Venture Partners and Lightspeed led the round with Atomico, Mark Zuckerberg, Priscilla Chan and Claudia Schiffer.
It will open U.S. clinics, a New York site in 2026, offering scans for £299.
350,000 have registered; users can take results to the NHS though no data-sharing agreement exists.

1 / 3